Home

scorta dominare Sputare spinraza clinical trial results candidato Obligate Manciata

Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds
Spinraza Can Restore Motor Function in Children With Late-Onset SMA, Study Finds

Risdiplam trials: early results of Sunfish – TreatSMA
Risdiplam trials: early results of Sunfish – TreatSMA

Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink
Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden | SpringerLink

Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy
Therapeutic approaches for spinal muscular atrophy (SMA) | Gene Therapy

Risdiplam trials: exciting early results in Firefish – TreatSMA
Risdiplam trials: exciting early results in Firefish – TreatSMA

SPINRAZA® (nusinersen) Safety Profile | HCP
SPINRAZA® (nusinersen) Safety Profile | HCP

Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate
Threats to Spinraza are mounting, but Biogen still has cards to play | Evaluate

Biogen and Ionis Pharmaceuticals: A Message to the SMA Community - Muscular Dystrophy Association
Biogen and Ionis Pharmaceuticals: A Message to the SMA Community - Muscular Dystrophy Association

Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP

Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients
Biogen Announces New Data Further Establishing SPINRAZA® (nusinersen) as a Foundation of Care in Spinal Muscular Atrophy for a Broad Range of Patients

Clinical Trials for Spinal Muscular Atrophy - Cure SMA
Clinical Trials for Spinal Muscular Atrophy - Cure SMA

SMA patients can switch from Spinraza to Zolgensma' < Hospital < 기사본문 - KBR
SMA patients can switch from Spinraza to Zolgensma' < Hospital < 기사본문 - KBR

Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study - Neuromuscular Disorders
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study - Neuromuscular Disorders

Biogen Announces New Spinraza Data Ahead of Presentation | BioSpace
Biogen Announces New Spinraza Data Ahead of Presentation | BioSpace

Drug Trials Snapshots: SPINRAZA | FDA
Drug Trials Snapshots: SPINRAZA | FDA

Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found
Higher-dose Spinraza SMA Trial Now Enrolls After No Safety Issues Found

Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP

Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP
Later-Onset SPINRAZA® (nusinersen) Efficacy | HCP

Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)
Later-Onset SMA (Types 2 & 3)| SPINRAZA® (nusinersen)

Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy | Nature Neuroscience
Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy | Nature Neuroscience

Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology
Frontiers | Drug Screening and Drug Repositioning as Promising Therapeutic Approaches for Spinal Muscular Atrophy Treatment | Pharmacology

Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers | Fierce Pharma
Biogen's Spinraza scores later-onset SMA data for stepped-up push with payers | Fierce Pharma

Combinatorial treatment for spinal muscular atrophy - Poletti - 2020 - Journal of Neurochemistry - Wiley Online Library
Combinatorial treatment for spinal muscular atrophy - Poletti - 2020 - Journal of Neurochemistry - Wiley Online Library

Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study - The Lancet

Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) - Clinical Trials Arena
Spinraza (nusinersen) for the Treatment of Spinal Muscular Atrophy (SMA) - Clinical Trials Arena

From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology
From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1 - Pediatric Neurology